

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT BY APPLICANT	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VPI/99-105 DIV	SERIAL NO. Not Yet Assigned
	APPLICANTS Michael R. Hale, et al.	CONFIRMATION NO. Not Yet Assigned	
	FILING DATE Concurrently Herewith	GROUP Not Yet Assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/FTP/	3,743,722	07/3/73	Mohrs et al.	424	98	
	4,330,542	05/18/82	Descamps et al.	424	248.5	
	4,629,724	12/16/86	Ryono et al.	514	18	
	5,196,438	03/23/93	Martin et al.	514	311	
	5,354,866	10/11/94	Kempf et al.	546	265	
	5,622,949	04/22/97	Talley et al.	514	237.8	
	5,723,490	03/03/98	Tung et al.	514	478	
	5,744,481	04/28/98	Vazquez et al.	514	311	
↓	5,808,056	09/15/90	Amato et al.	540	360	
/FTP/	5,843,946	12/01/98	Vazquez et al.	514	252.11	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/FTP/	0 022 118	1/7/81	EP				
	0 181 071	3/14/86	EP				
	0 264 795	4/27/88	EP				
	0 346 847	12/20/89	EP				
	0 364 804	4/25/90	EP				
	0 434 365	6/26/91	EP				
	0 468 641	1/29/92	EP				
	0 486 948	5/27/92	EP				
	0 541 168	5/12/93	EP				
	0 594 540	4/27/94	EP				
↓	3542567	6/5/86	DE				
	2,167,759	6/4/86	GB	↓	↓		
/FTP/	2,200,115	7/27/88	GB	_____	_____		

EXAMINER /Fiona T. Powers/

DATE CONSIDERED 05/10/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. VPI/99-105 DIV	SERIAL NO. Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANTS Michael R. Hale, et al.	CONFIRMATION NO. Not Yet Assigned
				FILING DATE Concurrently Herewith	GROUP Not Yet Assigned
/FTP/	WO90/07329	7/12/90	PCT		
	WO91/00725	1/24/91	PCT		
	WO91/18866	12/12/91	PCT		
	WO92/08688	5/29/92	PCT		
	WO92/08698	5/29/92	PCT		
	WO92/08699	5/29/92	PCT		
	WO92/08700	5/29/92	PCT		
	WO92/08701	5/29/92	PCT		
	WO92/17176	10/15/92	PCT		
	WO93/23368	11/25/93	PCT		
	WO93/23388	11/25/93	PCT		
	WO93/23379	11/25/93	PCT		
	WO94/04491	3/3/94	PCT		
	WO94/04492	3/3/94	PCT		
	WO94/04493	3/3/94	PCT		
	WO94/05639	3/17/94	PCT		
	WO94/10134	5/11/94	PCT		
	WO94/10136	5/11/94	PCT		
	WO94/18192	8/18/94	PCT		
	WO94/19322	9/1/94	PCT		
	WO95/06030	3/2/95	PCT		
	WO95/07269	3/16/95	PCT		
	WO95/09843	4/13/95	PCT		
	WO95/14016	5/26/95	PCT		
	WO95/32185	11/30/95	PCT		
	59046252	3/15/84	JP		
	59048449	3/19/84	JP		
/FTP/	61071830	4/12/86	JP		

EXAMINER

/Fiona T. Powers/

DATE CONSIDERED 05/10/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VPI/99-105 DIV	SERIAL NO. Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANTS Michael R. Hale, et al.	CONFIRMATION NO. Not Yet Assigned
		FILING DATE Concurrently Herewith	GROUP Not Yet Assigned

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
/FTP/	Banker et al., <u>Modern Pharmaceutics</u> , pp. 627-629 (1996).
	R. Bone et al., "X-ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C <sub>2</sub> Symmetry", <u>J. Am. Chem. Soc.</u> , 113, pp. 9382-84 (1991).
	J.C. Craig et al., "Antiviral Synergy Between Inhibitors of HIV Proteinase and Reverse Transcriptase", <u>Antiviral Chem. and Chemotherapy</u> , 4(3), pp. 161-66 (1990).
	S. Crawford et al., "A Deletion Mutation in the 5' Part of the pol Gene of Moloney Murine Leukemia Virus Blocks Proteolytic Processing of the gag and pol Polyproteins", <u>J. Virol.</u> , 53, pp. 899-907 (1985).
	M. Cushman et al., "Development of Methodology for the Synthesis of Stereochemically Pure PhenylCH <sub>2</sub> N <sub>3</sub> Pro Linkages in HIV Protease Inhibitors", <u>J. Org. Chem.</u> , 56, pp. 4161-67 (1991).
	D.S. Dhanoa et al., "The Synthesis of Potent Macrocyclic Renin Inhibitors", <u>Tetrahedron Lett.</u> , 33, pp. 1725-28 (1992).
	G.B. Dreyer et al., "Hydroxyethylene Isostere Inhibitors of Human Immunodeficiency Virus-1 Protease: Structure-Activity Analysis Using Enzyme Kinetics, X-ray Crystallography, and Infected T-Cell Assays", <u>Biochemistry</u> , 31, pp. 6646-59 (1992).
	G.A. Flynn et al., "An Acyl-Iminium Ion Cyclization Route to a Novel Conformationally Restricted Dipeptide Mimic: Applications to Angiotensin-Converting Enzyme Inhibition", <u>J. Am. Chem. Soc.</u> , 109, pp. 7914-15 (1989).
	G. Fontenot et al., "PCR Amplification of HIV-1 Proteinase Sequences Directly from Lab Isolates Allows Determination of Five Conserved Domains", <u>Virology</u> , 190, pp. 1-10 (1992).
	J. Freskos et al., "(Hydroxyethyl)sulfonamide HIV-1 Protease Inhibitors: Identification of the 2-Methylbenzoyl Moiety at P-2", <u>Bio. &amp; Med. Chem. Lett.</u> , 6, pp. 445-450 (1996).
	A. Ghosh et al., "Potent HIV Protease Inhibitors Incorporating High-Affinity P <sub>2</sub> -Ligands and (R)-(Hydroxyethylamino)sulfonamide Isostere", <u>Bio. &amp; Med. Chem. Lett.</u> , 8, pp. 687-690 (1998).
	E.E. Gilbert, "Recent Developments in Preparative Sulfonation and Sulfation", <u>Synthesis</u> , 1969, pp. 3-10 (1969).
	A. Goldblum, "Modulation of the Affinity of Aspartic Proteinases by the Mutated Residues in Active Site Models", <u>FEBS</u> , 261, pp. 241-44 (1990).
	D. Grobelny et al., "Selective Phosphinate Transition-State Analogue Inhibitors of the Protease of Human Immunodeficiency Virus", <u>Biochem. Biophys. Res. Commun.</u> , 169, pp. 1111-16 (1990).
↓	G.D. Hartman et al., "4-Substituted Thiophene- and Furan-2-sulfonamides as Topical Carbonic Anhydrase Inhibitors", <u>J. Med. Chem.</u> , 35, pp. 3822-31 (1992).
/FTP/	S. J. Hays et al., "Synthesis of cis-4-(Phosphonoxy)-2-piperidinecarboxylic Acid, an N-Methyl-D-aspartate Antagonist", <u>J. Org. Chem.</u> , 56, pp. 4984-4086 (1991).

EXAMINER

/Fiona T. Powers/

DATE CONSIDERED 05/10/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VPI/99-105 DIV	SERIAL NO. Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANTS Michael R. Hale, et al.	CONFIRMATION NO. Not Yet Assigned
		FILING DATE Concurrently Herewith	GROUP Not Yet Assigned

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
/FTP/	J.R. Huff, "HIV Protease: A Novel Chemotherapeutic Target for AIDS", <u>Journal of Medicinal Chemistry</u> , 34(8), pp. 2305-14 (1991).
	K.Y. Hui et al., "A Rational Approach in the Search for Potent Inhibitors Against HIV Proteinase", <u>FASEB</u> , 5, pp. 2606-10 (1991).
	Y. Kiso et al., "O→N Intramolecular Acyl Migration'-type Prodrugs of Tripeptide Inhibitors of HIV Protease", <u>Peptides: Chemistry, Structure and Biology</u> , 61, pp. 157-159 (1996).
	N.E. Kohl et al., "Active HIV Protease Is Required for Viral Infectivity", <u>Proc. Natl. Acad. Sci. USA</u> , 85, pp. 4686-90 (1988).
	X. Lin et al., "Enzymic Activities of Two-Chain Pepsinogen, Two-Chain Pepsin, and the Amino-Terminal Lobe of Pepsinogen", <u>J. Biol. Chem.</u> , 267(24), pp. 17257-63 (1992).
	K.P. Manfredi et al., "Examination of HIV-1 Protease Secondary Structure Specificity Using Conformationally Constrained Inhibitors", <u>J. Med. Chem.</u> , 34, pp. 3395-99 (1991).
	F.R. Marshall, "Computer-Aided Drug Design", <u>Ann. Ref. Pharmacol. Toxicol.</u> , 27, pp. 193-213 (1987).
	J.A. Martin, "Recent Advances in the Design of HIV Proteinase Inhibitors", <u>Antiviral Research</u> , 17, pp. 265-78 (1992).
	T.D. Meek et al., "Inhibition of HIV-1 Protease in Infected T-Lymphocytes by Synthetic Peptide Analogues", <u>Nature</u> , 343, pp. 90-92 (1990).
	M. Miller et al., "Structure of Complex of Synthetic HIV-1 Protease with a Substrate-Based Inhibitor at 2.3 Å Resolution", <u>Science</u> , 246, pp. 1149-52 (1989).
	M. Miller et al., "Crystal Structure of a Retroviral Protease Proves Relationship to Aspartic Protease Family", <u>Nature</u> , 337, pp. 576-79 (1989).
	K.H.M. Murthy et al., "Crystal Structures at 2.2-Å Resolution of Hydroxyethylene-Based Inhibitors Bound to Human Immunodeficiency Virus Type 1 Protease Show That the Inhibitors Are Present in Two Distinct Orientations", <u>J. Biol. Chem.</u> , 267, pp. 22770-78 (1992).
	J.B. Nichols et al., "A Molecular Mechanics Valence Force Field for Sulfonamides Derived by <u>ab initio</u> Methods", <u>J. Phys. Chem.</u> , 95, pp. 9803-11 (1991).
	J. Palca, "Shooting at a New HIV Target", <u>Science</u> , 247, p. 410 (1990).
	L.H. Pearl et al., "A Structural Model for the Retroviral Proteases", <u>Nature</u> , 329, pp. 329-51 (1987).
	J.W. Perich et al., "The Synthesis of Multiple O-Phosphoseryl-Containing Peptides via Phenyl Phosphate Protection", <u>J. Org. Chem.</u> , 53, pp. 4103-4105 (1988).
↓	M.S. Plummer et al., "Design of Peptidomimetic Ligands for the pp60 <sup>sc</sup> SH2 Domain", <u>Bioorganic &amp; Medicinal Chemistry</u> , 5, pp. 41-47 (1997).
/FTP/	M. Popvic et al., "Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS", <u>Science</u> , 224, pp. 497-500 (1984).

EXAMINER

/Fiona T. Powers/

DATE CONSIDERED

05/10/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VPI/99-105 DIV	SERIAL NO. Not Yet Assigned
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANTS Michael R. Hale, et al.	CONFIRMATION NO. Not Yet Assigned
		FILING DATE Concurrently Herewith	GROUP Not Yet Assigned

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER INITIAL	
/FTP/	M.D. Power et al., "Nucleotide Sequence of SRV-1, a Type D Simian Acquired Immune Deficiency Syndrome Retrovirus", <u>Science</u> , 231, pp. 1567-73 (1986).
	N.A. Roberts, "Rational Design of Peptide-Based HIV Proteinase Inhibitors", <u>Science</u> , 248, pp. 358-61 (1990).
	S. Scharpe et al., "Proteases and Their Inhibitors: Today and Tomorrow", <u>Biochimie</u> , 73, pp. 121-26 (1991).
	S.K. Sharma et al., "Could Angiotensin I Be Produced from a Renin Substrate by the HIV-1 Protease?", <u>Anal. Biochem.</u> , 198, pp. 363-67 (1991).
↓ /FTP/	S. Yamaguchi et al., "Synthesis of HIV Protease Dipeptide Inhibitors and Prodrugs", <u>Peptide Chemistry</u> 1996, pp. 297-300 (1997).

**EXAMINER** /Fiona T. Powers/

DATE CONSIDERED 05/10/2007

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet

1

of

1

<i>Complete if Known</i>	
Application Number	10/691,333
Filing Date	October 21, 2003
First Named Inventor	Michael R. Hale
Art Unit	1626
Examiner Name	Fiona Powers
Attorney Docket Number	VPI/99-105 DIV

## U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
/FTP/		WO 96/22287	07-25-1996	G.D. Searle & Co.		
		WO 96/28418	09-19-1996	G.D. Searle & Co.		
		WO 96/28463	09-19-1996	G.D. Searle & Co.		
		WO 96/28464	09-19-1996	G.D. Searle & Co.		
		WO 96/28465	09-19-1996	G.D. Searle & Co.		
/FTP/		WO 97/18205	05-22-1997	G.D. Searle & Co.		

**Examiner  
Signature**

/Fiona T. Powers/

Date  
Considered

05/04/2007

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*